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A B S T R A C T   
Purpose: To retrospectively investigate the prevalence, demography, antiseizure medication (ASM) usage, 
healthcare resource utilization (HCRU), and mortality of patients with Lennox-Gastaut syndrome (LGS) in pri-
mary and secondary care in the UK. 
Methods: Patients with confirmed LGS were anonymously identified from the UK Clinical Practice Research 
Datalink (CPRD) GOLD database (01/01/1987–31/1b0/2018) using the LGS Read Code (F250500). Probable 
LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode 
Statistics [HES]/CPRD) plus rufinamide prescription. Period prevalence was calculated based on patients 
enrolled in CPRD GOLD and alive in 2017. CPRD data were linked to HES to calculate HCRU, and to the Office for 
National Statistics mortality registry. 
Results: Period prevalence of LGS was 0.578/10,000 (n = 180), with 74 and 106 patients identified with 
confirmed (0.289/10,000) and probable LGS (0.420/10,000). Mean (max) ASM usage was ~1 (3) per year. In 
confirmed LGS, valproate (72%), lamotrigine (69%), and clobazam (66%) were the most commonly prescribed 
ASMs. HCRU (per patient-year) was similar in confirmed and probable LGS and mostly consisted of primary care 
general practitioner consultations (4–6), outpatient visits (5–10), inpatient admissions (1–4), and A&E visits (1). 
During the follow-up period, 18 patients died with crude mortality rates of 6.12 (confirmed LGS) and 4.17 
(probable LGS) deaths per 1000 person-years. 
Conclusion: Prevalence of LGS appears low in the UK. The similarly high HCRU and mortality rates in confirmed 
and probable LGS support the validity and specificity of the probable LGS algorithm and high burden of LGS.   
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Introduction 
Lennox-Gastaut syndrome (LGS) is a rare childhood-onset epileptic 
encephalopathy (1–10% of childhood epilepsy cases depending on 
age),1 typically diagnosed in children under 8 years of age.2 It is one of 
the most severe and difficult epileptic disorders to identify and 
manage2,3 because of its highly variable presentation1–3 and evolving 
features over time.2,3 In addition, a number of seizure types may present 
at the onset of LGS,2 often resistant to treatment,2 resulting in variable 
outcomes following treatment.4 In general, there is a poor prognosis for 
patients with LGS. Most patients require polytherapy,5 live with seizures 
into adulthood,6 and are at a high risk of developing an intellectual 
disability.1 LGS is also associated with risk factors for sudden unex-
plained death in epilepsy7 that underlie the 15% rate of early mortality.8 
While developments have been made in understanding the etiology 
of LGS, there is a scarcity of data on the prevalence9,10 and healthcare 
resource utilization (HCRU) in patients with LGS.11 As LGS is a severe 
form of epilepsy with frequent intractable seizures,6 it is likely that 
HCRU (eg general practitioner [GP] visits, secondary care referrals and 
hospitalizations) is high considering the increased HCRU in patients 
with epilepsy and increased seizure frequency.12 
One of the reasons there are few studies reporting on the prevalence 
and HCRU in patients with LGS is the difficulty in identifying patients for 
population studies, partly because of the rarity of the syndrome,13 dif-
ficulties in defining the syndrome,14,15 and the historical absence of a 
method to record the diagnosis. While this is historically true, there are 
signs that more specific diagnoses are being made for patients previously 
diagnosed with epilepsy. For example, in the UK, the large decline in the 
cumulative and annual incidence of recorded epilepsy in primary care 
between 1994 and 2008 has been partially attributed to more specific 
diagnoses.16 
LGS was defined by the International League Against Epilepsy (ILAE) 
in 1989,17 and although the International Classification of Diseases, 10th 
Revision (ICD-10) was published in 1990, an International Classification 
of Disease code for LGS (G40.812) was not included until 2015.11,18 Until 
sufficient time has passed to allow for the LGS code to become adopted,11 
healthcare databases not reliant on ICD-10 coding may provide the best 
source of data to investigate the prevalence and HCRU in LGS. 
In the UK, a clinical terminology coding system (Read Codes) captures 
details within patients’ electronic medical records (EMRs) of any primary 
and secondary care interactions, including records of patient symptoms, 
diagnosis, and prescriptions.19 Since 2011, to ensure validity of the coded 
data, the ILAE has recommended that diagnoses of epilepsy are made by a 
healthcare professional with appropriate specialized training, and where 
diagnosis is definite, it should be recorded within primary care docu-
mentation.20 However, while accurate identification of epilepsy is 
important for epidemiologic studies, it is not always possible and may 
result in errors in the coding process.20 For this reason, the specificity and 
predictive value of diagnostic codes must be considered, and the ILAE 
further recommended that linked data should be validated in each pop-
ulation studied. 
Use of the Read Code system for epilepsy diagnoses has been vali-
dated by several epidemiologic studies16,21 and has demonstrated good 
sensitivity (86%) and specificity (97%).21 A UK primary care database 
that has access to Read Codes is the Clinical Practice Research Datalink 
(CPRD).19 As a Read Code for LGS has been available in the UK since 
2009, the use of this database may permit a better understanding of 
HCRU in LGS. This is particularly true given that the primary care data 
can be linked to a range of other health-related data, including Hospital 
Episode Statistics (HES) and the mortality registry from the Office for 
National Statistics (ONS).22,23 Until now, no study has investigated the 
prevalence of HCRU in LGS using the Read Code system, and studies 
have relied on secondary methods that utilize algorithms (based on 
epilepsy diagnosis and antiseizure medication [ASM] usage from claims 
data) to identify patients with probable LGS.11,13 While useful, these 
studies have limitations as it is likely that not all patients will be 
prescribed the ASM in the algorithm. The objective of this retrospective 
cohort study was to use linked CPRD data to examine prevalence, 
demography, ASM usage, HCRU, and mortality of patients with LGS 
identified from the CPRD and HES databases, with additional data from 
the ONS. 
Methods 
Data source − CPRD 
CPRD is a real-world database providing a quality-assured and vali-
dated source of longitudinal and representative UK population health 
data for epidemiologic and HCRU research.22 Coded and anonymized 
patient EMRs are provided to the CPRD by a UK-wide network of more 
than 1700 primary care practices that have routinely collected data since 
1987.19,22 Patients with a known diagnosis of LGS or epilepsy that pre-
dated the introduction of CPRD could have their diagnosis entered into 
the system at or after its introduction. Thus, patients with an epilepsy 
diagnosis in CPRD could have been diagnosed before 1987. The present 
study used CPRD GOLD data, which includes EMRs contributed to CPRD 
using the Vision® GP IT software.24 Using this software and recording 
information with coding systems such as version 2 Read Codes,22 EMR 
data (patient demographics, diagnoses and symptoms, prescriptions, 
laboratory tests, and referrals to hospital and specialist care) are recorded 
by the GP against a patient’s unique National Health Service (NHS) 
number,22 which is available for 99.8% of primary care records.25 In the 
present study, using the latest build of CPRD GOLD (11/03/2019), 13.7 
million de-identified patient EMRs were used following collection from 
01/01/1987–28/02/2019. 
Data source – HES and ONS 
For consenting patients and practices, linkages between CPRD GOLD 
and other health-related data (eg HES/ONS) were conducted via a third 
party (NHS Digital)19 using patients’ unique NHS numbers. As NHS 
numbers were introduced in 1996/7, linked data are not available for all 
patients registered in CPRD, resulting in fewer patients and a restricted 
period for HES linked and ONS linked data.19 HES data include records 
of all admissions or attendances at participating NHS hospitals, records 
of patient care, type of outpatient consultation, specialists seen, clinical 
diagnoses, and procedures performed.19 A&E visits are only reported in 
HES if they result in a subsequent hospital admission.26 
Patient population 
From this cohort, patients enrolled between 01/01/1987 and 31/10/ 
2018 were included. Patients were defined with confirmed LGS if their 
EMR contained a Read Code for LGS (CPRD GOLD; code F250500). 
Patients with probable LGS were defined as those with an EMR con-
taining an ICD-10 code/Read Code for epilepsy (from HES/CPRD) and a 
formulary product code for rufinamide within a year of diagnosis. Pre-
scription of rufinamide was deemed the best indicator of LGS in patients 
with epilepsy, owing to its specific indication in patients with LGS27 and 
use in previous claims database studies to identify probable LGS.11,13 
Patients with a prescription of stiripentol or potassium bromide were 
excluded to prevent inclusion of patients with probable Dravet syn-
drome. Regardless of the length of a patient’s EMR, all patients with a 
record of LGS in the CPRD were included for analyses of prevalence. The 
index date for confirmed or probable LGS reflected the date of the last 
visit to a neurologist/pediatrician in the year preceding the first CPRD 
record of the epilepsy diagnosis. 
Outcomes 
The primary outcome was period prevalence of LGS. As many pa-
tients with LGS may have incomplete records, accurately identifying 
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the date of diagnosis and determining incidence is challenging. Also, 
considering the potential impact of mortality, prevalence was consid-
ered the preferred measure of determining the magnitude of LGS in the 
population that may result in HCRU. 
Period prevalence of LGS was calculated for the last full calendar 
year of data from CPRD: 2017. Period prevalence was calculated using 
the number of confirmed/probable cases identified from CPRD GOLD 
and/or HES in 2017 (new and pre-existing) divided by the total number 
of patients within CPRD GOLD in 2017 (both in terms of units of person - 
time) and expressed as cases per 10,000 people. Patients who were 
deceased in 2017 were excluded from the calculations of prevalence. 
Secondary outcomes included ASM usage (proportion of patients 
with ASM prescriptions during the follow-up period), HCRU (primary 
and secondary care - related visits/entries), and mortality reported over 
the follow-up period. For confirmed LGS, HCRU was estimated (per 
patient-year) after the date of LGS diagnosis; for probable LGS, the 
period from index date was utilized to estimate HCRU. As the avail-
ability of NHS numbers restricted linkage to a shorter period, HES and 
ONS linked data were available for a follow-up period of 01/04/ 
1997–31/12/2017 and 02/01/1998–13/02/2018, respectively. Unlike 
the analyses to estimate period prevalence, patients who died during the 
follow-up period were included in calculations of ASM prescriptions and 
HCRU. 
Primary care data (CPRD) were used to calculate ASM prescriptions, 
the number of consultations, and visits or telephone calls with GPs or 
nurses. For patients with HES-linked CPRD data, hospital inpatient ad-
missions (number and duration [with a single consultant]), hospital 
outpatient visits, and A&E admissions were calculated. Hospital visits 
could have a maximum of 20 diagnoses and 24 procedures recorded 
against the visit and were not specifically epilepsy related, thus reflecting 
total HCRU. 
Mortality rates were calculated for those patients with ONS linked 
data as the rate per 1000 person-years of follow up. 
Baseline characteristics included age at diagnosis of epilepsy or 
LGS, follow-up duration, and sex. All available medical history was 
extracted for each patient identified, including demographic (sex and 
age at diagnosis) and clinical data (diagnoses, symptoms, prescription 
medication). 
Data analyses 
Two-tailed Student’s t-tests (p < 0.05) were used to determine sta-
tistical differences, for baseline characteristics and outcomes, between 
patients with confirmed or probable LGS. To determine if there was a 
significant relationship between the age of patients in 2017 and the 
prevalence of LGS in the full cohort, a Chi-square test was used. In 
addition to stratification of outcomes by confirmed and probable LGS, 
prevalence was stratified by age group in 2017 (0–5, 6–11, 12–17, and 
≥18 years), HCRU was stratified by age group at follow up (<12 years 
and ≥12 years), and inpatient admissions were stratified according to 
the presence of an epilepsy-related ICD-10 code (codes starting with 
G40) as the primary admission diagnosis. 
Ethics and guidelines 
CPRD has ethics approval from the UK’s Health Research Authority 
(HRA) Research Ethics Committee to provide primary care and linked 
data for observational research.22,23 An Independent Scientific Advisory 
Committee provided approval of the study (Reference number:18_236R). 
The guidelines for Strengthening the Reporting of Observational Studies 
in Epidemiology (STROBE) were followed.28 
Figure 1. Overview of population by study objective 
ASM, antiseizure medication; CPRD, Clinical Practice Research Datalink; HCRU, healthcare resource utilization; HES, Hospital Episode Statistics; ICD-10, Interna-
tional Classification of Diseases, 10th Revision; LGS, Lennox-Gastaut syndrome; ONS, Office for National Statistics. 
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A total of 256 patients were identified with confirmed (110; 43%) or 
probable (146; 57%) LGS (Figure 1). 
Baseline characteristics are presented in Table 1. For those with 
confirmed LGS, mean (SD) age at diagnosis of LGS was 13.8 (12.3) years, 
whereas the age at diagnosis of epilepsy was 7.0 (10.0) years. Patients 
with probable LGS had a similar age at epilepsy diagnosis to those with 
confirmed LGS (8.9 [11.0] years, p = 0.14). 
Similar proportions of patients with confirmed LGS (66%) or prob-
able LGS (56%) were male (p = 0.12) and follow-up duration, from 
epilepsy index date, was similar in both groups (confirmed: 11.4 [8.6] 
years; probable 11.9 [7.8] years, p = 0.66). 
Prevalence 
Extracted data from CPRD GOLD for those alive in 2017 constituted 
EMRs from 2,847,249 patients. Of the 256 patients identified in the full 
(confirmed + probable) cohort, 76 had died prior to 2017, leaving 180 
patients (74 confirmed) alive for calculation of period prevalence 
(Figure 1 and Table 2). In general, period prevalence increased with 
age in the 0–17 years age group; however, a greater proportion of pa-
tients with probable LGS were in the 6–11 years group and a greater 
proportion of patients with confirmed LGS were in the ≥18 years group. 
These differences resulted in a significant dependence (p = 0.044) 
between age in 2017 and prevalence between the confirmed and prob-
able LGS cohorts. 
Comparing the index date for epilepsy in those with confirmed or 
probable LGS, cases increased steadily from 1959 and reached a peak for 
both groups in 2003–4 (confirmed LGS, n = 12; probable LGS, n = 15; 
Figure 2); after which, cases plateaued and fell in recent years. Before 
the introduction of a Read Code for LGS in 2009, 93 patients with 
confirmed LGS were diagnosed with epilepsy (85%) (Figure 2); of those, 
70 had a Read Code for LGS in the same period (75%). 
ASM usage 
A total of 20 different ASMs were used by at least 10% of the 
confirmed and probable LGS cohorts during the follow-up period 
(Figure 3). ASMs used by at least half of those with confirmed LGS during 
follow up were (high to low, % of patients): valproate (72%), lamotrigine 
(69%), clobazam (66%), midazolam (64%), levetiracetam (55%), and 
diazepam (54%). Of note, rufinamide was used by 27% of those with 
confirmed LGS. With the exception of rufinamide, ASM usage in probable 
LGS was similar for the ASMs listed for confirmed LGS. In addition, 
several less commonly used ASMs were prescribed more widely for those 
with probable versus confirmed LGS, eg carbamazepine (46 vs 29%), 
oxcarbazepine (19 vs 6%), and pregabalin (14 vs 4%). During follow up, 
the mean (SD) number of ASMs used by a patient with confirmed LGS was 
6.7 (3.4), and only a small minority (3.7%) of patients were prescribed 
only one ASM during this period. Similar data were found in the probable 
cohort with 8.5 (3.5) ASMs used during follow up. 
Table 2 
Period prevalence of LGS from UK CPRD by identification criteria and age group in 2017   
Confirmed LGSa (n ¼ 74) Probableb LGS (n ¼ 106) Full cohort (Confirmed þ probable LGS; n ¼ 180) p-value 
Prevalence, per 10,000 people 
Standardized to UK CPRD population 0.289 0.420 0.578  
Age distribution, n (prevalence per 10,000 people) 
0-5 years 
6-11 years 















Abbreviations: CPRD, Clinical Practice Research Datalink; ICD-10, International Classification of Diseases, 10th Revision; LGS, Lennox-Gastaut syndrome. aDiagnosis 
confirmed by the Read Code for LGS: F250500. bLGS considered probable based on the ICD-10/Read Code for epilepsy and at least one prescription of rufinamide 
within a year of diagnosis. cChi-square test of prevalence. 
Table 1 
Baseline characteristics and length of follow up of patients with LGS   
Confirmed LGSa (n ¼ 110) Probable LGSb (n ¼ 146) Full cohort (confirmed þ probable LGS; n ¼ 256) p-value 
Age at diagnosis of LGS, yea 
Mean (SD) 13.8 (12.3) NA NA NA 
Median 10 NA NA  
Min; Max 0; 61 NA NA  
Age at index date (epilepsy diagnosis), years 
Mean (SD) 7.0 (10.0) 8.9 (11.0) 8.1 (10.6) 0.14c 
Median 3.5 4 4  
Min; Max 0; 61 0; 54 0; 61  
Follow-up duration after index, years 
Mean (SD) 11.4 (8.6) 11.9 (7.8) 11.7 (8.2) 0.66 
Median 9.5 9.7 9.6  
Min; Max 0.2; 32.2 0.6; 32.2 0.2; 32.2  
Sex, number (%) 
Male 72 (65) 81 (55) 153 (60%) 0.12d 
Female 38 (35) 65 (45) 103 (40%)  
Abbreviations: ICD-10, International Classification of Diseases, 10th Revision; LGS, Lennox-Gastaut syndrome; NA, not applicable; SD, standard deviation. aDiagnosis 
confirmed by the Read Code for LGS: F250500. bLGS considered probable based on ICD-10/Read Code for epilepsy and at least one prescription of rufinamide within a 
year of diagnosis. cTwo-tailed Student’s t-test of confirmed versus probable cohorts. dChi-square test of confirmed versus probable cohorts. 
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The mean (SD) number of ASMs used each year for those with 
confirmed LGS was 1.06 (0.27) and 1.12 (0.39) during 2010–13 and 
2014–17; no patients used more than two ASMs (min; max of 0.25; 1.5 
and 0.25; 2.00). Similarly, for those with probable LGS, there was a 
tendency for only one ASM to be used per year: 1.06 (0.27) and 1.22 
(0.48) during 2010–13 and 2014–17; however, the upper range was 
increased to approximately three ASMs (min; max of 0.25; 1.5 and 
0.25; 3.25). 
Healthcare resource utilization 
GP consultation was the most common contact method in primary 
care, followed by GP phone calls and nurse consultations; GP visits were 
rare, as were nurse visits or phone calls (Table 3A). Primary care HCRU 
was similar for confirmed LGS and probable LGS, with no significant 
difference found between the two groups irrespective of age at the time of 
HCRU. In secondary care, outpatient visits were the most common type of 
Figure 2. Period of epilepsy diagnoses in those with confirmed or probable LGS 
ICD-10, International Classification of Diseases, 10th Revision; LGS, Lennox-Gastaut syndrome. Period of diagnosis based on the timing of the ICD-10/Read Code for 
epilepsy prior to prescription of rufinamide. 
Figure 3. ASM usage during the follow-up period 
ASM, antiseizure medication; ICD-10, International Classification of Diseases, 10th Revision; LGS, Lennox-Gastaut syndrome. aDiagnosis confirmed by the Read Code 
for LGS: F250500. bLGS considered probable based on the ICD-10/Read Code for epilepsy and at least one prescription of rufinamide within a year of diagnosis. 
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HCRU, followed by inpatient admissions and A&E visits (Table 3B). As 
with primary care consultations, for either age group and whether or not 
inpatient admissions were related to epilepsy, HCRU was generally 
similar when comparing confirmed with probable LGS. The exception 
was that the length of stay of inpatient admissions was significantly 
longer for probable versus confirmed LGS in the ≥12 years age group (all 
causes, p = 0.041; epilepsy related, p = 0.002). 
Mortality 
Considering only deaths identified in patients with CPRD linkage to 
ONS, 18 of 122 patients died over the follow-up period (confirmed: n =
11; probable: n = 7). Median age at death (min; max) for confirmed LGS 
was 26 (11; 46) and 16 (4; 64) years in probable LGS. Crude mortality 
rates of 6.12 (confirmed LGS) and 4.17 (probable LGS) deaths per 1000 
person-years were calculated over a follow-up period consisting of 1796 
and 1679 patient-years. 
Discussion 
To our knowledge, this is the first study to use large-scale and 
routinely collected UK healthcare data to identify patients with 
confirmed LGS and assess their HCRU. This study confirms a minimum 
prevalence of 0.289 per 10,000 people, multiple prescribed ASMs, high 
HCRU, and a high mortality rate in patients with LGS. Similar findings 
were found in patients with probable LGS, identified based on diagnosis 
of epilepsy and prescription of rufinamide, thus supporting the validity 
and specificity of this algorithm-based approach. Based on the preva-
lence of confirmed and probable LGS, we find a total prevalence of 0.578 
per 10,000 people for LGS in the UK. 
CPRD is a large representative and validated source of UK healthcare 
data22 that allows linkage between primary care data (CPRD), secondary 
care data (HES), and general population mortality data (ONS).23 Using 
this approach and the availability of a Read Code for LGS, we identified 
110 patients with confirmed LGS and a further 146 patients with 
probable LGS, resulting in a large cohort of patients for analyses. 
Compared with previous studies in the USA and Finland, the prevalence 
of LGS in the UK CPRD was an order of magnitude lower than reported 
elsewhere (2.6–2.8 per 10,000 people).9,10 The reasons for this low 
prevalence in the UK may reflect a multitude of issues, including the 
possibility that our studied population is somehow intrinsically different 
than previously studied populations, potential underdiagnosis, miscod-
ing of LGS (for the confirmed LGS cohort), and lack of sensitivity of the 
Read Code system for identifying LGS especially prior to the introduc-
tion of an LGS code in 2009. 
Although seemingly rare in this study, misdiagnosis may be attrib-
utable to the manual nature of data entry from secondary care, thereby 
resulting in incomplete or inaccessible data.22 This would be consistent 
with why other studies from CPRD similarly find a lack of specificity with 
epilepsy coding.29 Patient-identifiable data (eg letters or free text entries) 
may be omitted from EMRs owing to data governance reasons22,24 and a 
lack of GP incentives to be more exact with the coding of data taken from 
secondary care.16 While this may explain some of the patients that we 
may have missed in our minimum estimate of the period prevalence of 
LGS, it is clear a sizeable proportion of patients do have their records 
retrospectively updated with the appropriate Read Code data (for 
example, 75% of patients with an epilepsy diagnosis prior to 2009 also 
had a Read Code for LGS in this period). 
The probable LGS cohort in this study attempted to overcome these 
challenges of misdiagnosis and miscoding. However, the combined 
prevalence of confirmed and probable cases was still lower than previ-
ously reported.9,10 We took a conservative approach of using prescrip-
tion of rufinamide, an ASM specifically indicated for LGS27, as a marker 
for probable LGS; only 27% of patients with confirmed LGS used rufi-
namide. The low use of rufinamide in confirmed LGS might result from 
the fact that much of the available CPRD data predate the license date of 
rufinamide in Europe (2007).27 Further, our data reflect the evolution of 
LGS diagnosis from epilepsy to the specific epilepsy syndrome of LGS;14 
epilepsy was diagnosed on average 6.8 years before LGS. In some cases, 
the patient’s index date for confirmed LGS (data not shown) predated 
the introduction of the Read Code in 2009, suggesting some GPs retro-
spectively changed the coding for their patients. This retrospective 
Table 3 
Healthcare resource utilization by identification criteriaa,b and age group during follow upc  
(A) Primary care Confirmed LGSa Probable LGSb p-valued  
<12 years (n = 39) ≥12 years (n = 89) <12 years (n = 71) ≥12 years (n = 115) <12 years ≥12 years 
Number of primary care consultations, PPY       
All (nurse/GP) 6.46 (4.82) 6.79 (7.19) 7.75 (5.37) 7.99 (7.08) 0.22 0.23 
GP consultations 4.95 (4.15) 3.94 (4.96) 5.54 (4.32) 5.97 (6.09)   
GP home visits 0.21 (0.57) 0.76 (2.66) 0.27 (0.56) 0.29 (0.78)   
GP phone call 0.69 (0.83) 1.03 (2.94) 0.83 (1.46) 0.54 (0.93)   
Nurse consultations 0.56 (1.12) 0.82 (1.13) 0.66 (1.16) 0.96 (1.18)   
Nurse home visits 0 0.06 (0.28) 0.03 (0.17) 0.06 (0.27)   
Nurse phone call 0.10 (0.38) 0.01 (0.11) 0.24 (1.43) 0.02 (0.13)    
(A) Primary care Confirmed LGSa Probable LGSb p-valued 
(B) Secondary care Confirmed LGSa Probable LGSb p-valued  
<12 years (n = 20) ≥12 years (n = 55) <12 years (n = 23) ≥12 years (n = 47) <12 years ≥12 years 
Number of hospital outpatient visits, PPY       
All causes 7.45 (9.51) 5.36 (7.61) 10.04 (10.49) 7.13 (7.48) 0.40 0.24 
Number of hospital inpatient admissions, PPY       
All causes 1.65 (1.63) 1.09 (1.86) 3.61 (4.85) 1.26 (2.06) 0.093 0.67 
Epilepsy related 1.50 (1.47) 0.96 (1.78) 3.04 (4.43) 0.89 (1.37) 0.14 0.83 
Hospital inpatient LOS, days        
(n = 129) (n = 544) (n = 575) (n = 512)   
All causes 2.41 (5.87) 3.42 (8.53) 3.53 (11.06) 4.74 (11.94) 0.11 0.041  
(n = 120) (n = 458) (n = 473) (n = 353)   
Epilepsy related 2.48 (6.07) 3.24 (6.80) 3.69 (11.98) 5.70 (13.90) 0.12 0.002 
Number of A&E visits, PPY       
All causes 0.85 (1.18) 1.15 (2.17) 0.96 (1.69) 1.04 (2.54) 0.81 0.83 
Data are mean (SD). Abbreviations: GP, general practitioner; ICD-10, International Classification of Diseases, 10th Revision; LGS, Lennox-Gastaut syndrome; LOS, 
length of stay; PPY, per patient-year; SD, standard deviation. aDiagnosis confirmed by the Read Code for LGS: F250500. bLGS considered probable based on the ICD-10/ 
Read Code for epilepsy and at least one prescription of rufinamide within a year of diagnosis. cData are shown by age at resource utilization, resulting in some patients 
being included in both groups. dTwo-tailed Student’s t-tests comparing HCRU between confirmed and probable LGS. 
R.F.M. Chin et al.                                                                                                                                                                                                                               
Seizure: European Journal of Epilepsy 91 (2021) 159–166
165
coding is also supported by the finding that the pediatric syndrome of 
LGS was coded in patients aged up to a maximum of 61 years. Therefore, 
some patients with LGS were not managed according to specific LGS 
guidelines and may have been missed from the probable LGS cohort 
because rufinamide was not prescribed. While this might be anticipated 
to result in differences between the two cohorts, these were generally 
only subtle and not statistically significant. 
In general, ASM usage and HCRU in primary and secondary care 
were similar in confirmed and probable LGS. ASM usage aligned with 
established guidelines for the treatment of LGS, with most using no more 
than two or three ASMs at one time (most often being valproate and 
lamotrigine).14,30 These findings support the conclusion that despite the 
probable cohort lacking an LGS Read Code, these patients had a disease 
more characteristic of treatment-resistant epilepsy, likely resulting from 
LGS. Since treatment resistance is much more common in LGS (76–97% 
of adults31,32) than in epilepsy (23–26%29,33), it can be expected to 
result in a greater number and diversity of ASMs over the long term. In 
the present study, 7–8 ASMs were used in those with probable or 
confirmed LGS (during a follow-up period of 8–12 years); this is similar 
to other long-term studies of LGS13,34 and higher than that reported in 
patients with epilepsy where monotherapy is more common than 
polytherapy.33 
In addition to ASM usage, HCRU was also similar to previous 
algorithm-based LGS studies. In a US-based retrospective claims study, 
physician visits (≥8 per patient-year; PPY), inpatient admissions (~1 
PPY), outpatient (>5 PPY), and emergency visits (~1 PPY)11 were 
similar to those from the present study in the older age group with LGS. 
For secondary care, this HCRU is more frequent in the LGS population 
from CPRD than the general population in the UK (inpatient admissions 
~0.4 PPY, outpatient ~1.5 PPY, and emergency visits <0.2 PPY).26 
Although significantly higher HCRU and costs have been demon-
strated with LGS versus the general population, a similarly designed US 
study using patients with epilepsy as the control group found contrasting 
results.13 In the study by Piña-Garza et al. (2017), the number of hospital 
visits was similar in the LGS and epilepsy populations; however, costs 
remained significantly higher with LGS owing to differences in medical 
costs over the ~10-year observation period.13 While the present study 
has no control group, a previous study in the UK, using The Health 
Improvement Network (THIN) database, reported lower ASM usage 
(mean <2 ASMs) and HCRU (<1 visit PPY) in patients with epilepsy12 
than found here for LGS. Taken together, these studies indicate that the 
findings from CPRD are consistent with the hypothesis that both 
confirmed and probable LGS populations utilize significantly more 
healthcare resources. Subsequently, they are more likely to contribute to 
higher costs than the general public or populations with less severe 
epilepsy. Future studies are required to investigate this further. 
Mortality in patients with LGS has been reported to be ~13–15 times 
higher than the general population, depending on the presence or 
absence of infantile spasms.35 Results from the present study, using ONS 
linked data, demonstrate patients with LGS have a crude mortality rate of 
4–6 per 1000 person-years (over a follow up consisting of ~1700–1800 
patient-years) that is higher than that reported for the general population 
in England (0.6 per 1000 person-years)36 and the overall epilepsy pop-
ulation in the UK (0.9 per 1000 person-years)12 but comparable to the 
epilepsy population with at least one seizure per day (4.9 per 1000 
person-years).12 
Some of the study’s limitations have been described above, partic-
ularly the limitations of coding and prescription of rufinamide in the 
definition of probable LGS. It may be argued that inclusion of additional 
ASMs or an age cut-off for diagnoses (eg less than 8 years) could have 
been used; however, such approaches would have compromised the 
specificity and sensitivity of the algorithm. While CPRD is representative 
of the UK population, non-primary care data are not fully captured or 
may be inaccessible. We could not access patient-level diagnostic data 
(eg electroencephalogram and imaging), which limited our ability to 
confirm LGS diagnoses in primary care by any other means. In addition, 
the high proportion of retrospective coding of LGS may have contributed 
to inaccuracies in the index date for LGS. Additional limitations include 
the absence of a direct reference population and the absence of other 
HCRU data (eg allied health professional visits), which limits the study’s 
ability to capture the total burden of LGS illness to the healthcare 
system. 
Conclusion 
Our findings suggest that the prevalence of LGS in the UK is lower 
than previously reported, with our results being a minimum estimate. 
While our findings provide valuable information on the burden of illness 
of LGS, they are likely an underestimate. Future UK-based epidemio-
logical studies, reliant on changeable Read Code data, should consider 
the potential of the Read Code system to underestimate the prevalence 
of specific epilepsy syndromes. The algorithm utilized in the current 
study was highly specific for LGS as the confirmed and probable cases 
had similarly high ASM usage, HCRU, and mortality rates, all of which 
are similar to previously published data. However, the algorithm may be 
poorly sensitive for LGS given the low prevalence observed compared 
with other studies, although other possible explanations cannot be ruled 
out. Our findings highlight the complex nature and high burden of LGS 
management in primary and secondary care settings. 
Funding 
This study was funded by GW Pharmaceuticals, Cambridge, UK. 
Author Rowena Holland, employed by GW Pharma Ltd, had the 
following involvement with the study: study design, interpretation of 
data, the writing of the article, and the decision to submit it for 
publication. 
Data statement 
Data were obtained from CPRD after going through their process for 
obtaining access, which includes ethics approval. The data were ana-
lysed by Syneos on behalf of GW Pharma Ltd to answer this particular 
research question. While the same data cut could be obtained from 
CPRD, the current data are confidential. 
Disclosure of conflicts of interest 
RC has received consultancy fees from Eisai, GW Pharmaceuticals 
companies, and Zogenix. He has been a principal investigator for GW 
Research Ltd and is a shareholder in Rize Medical Cannabis and Live 
Sciences UCITS ETF. FG is an employee of Syneos Health. MM was an 
employee of Syneos Health at the time of study completion. RH is 
employed by GW Pharma Ltd, London, UK. OP has received consultancy 
fees from GW Pharmaceuticals companies and Arvelle therapeutics. 
All authors met the ICMJE authorship criteria and had full access to 
relevant data. Neither honoraria nor payments were made for authorship. 
Author contributions 
All authors contributed to the study concept, design, and interpre-
tation of the data. FG analysed the data. 
Acknowledgments 
Medical writing support was provided to the authors by Sam Mason, 
PhD of Helios Medical Communications, Macclesfield, UK, and funded 
by GW Pharmaceuticals, Cambridge, UK. 
R.F.M. Chin et al.                                                                                                                                                                                                                               
Seizure: European Journal of Epilepsy 91 (2021) 159–166
166
References 
[1] Jahngir MU, Ahmad MQ, Jahangir M. Lennox-Gastaut syndrome: in a nutshell. 
Cureus 2018;10(8):e3134. 
[2] Arzimanoglou A, French J, Blume WT, Cross JH, Ernst J-P, Feucht M, et al. Lennox- 
Gastaut syndrome: a consensus approach on diagnosis, assessment, management, 
and trial methodology. Lancet Neurol 2009;8(1):82–93. 
[3] Piña-Garza JE, Chung S, Montouris GD, Radtke RA, Resnick T, Wechsler RT. 
Challenges in identifying Lennox–Gastaut syndrome in adults: a case series 
illustrating its changing nature. Epilepsy Behav Case Rep 2016;5:38–43. 
[4] Khan S, Al Baradie R. Epileptic encephalopathies: an overview. Epilepsy Res Treat 
2012;2012:403592. 
[5] Gresham J, Eiland LS, Chung AM. Treating Lennox–Gastaut syndrome in epileptic 
pediatric patients with third-generation rufinamide. Neuropsychiatr Dis Treat 
2010;6:639–45. 
[6] Camfield P, Camfield C. Long-term prognosis for symptomatic (secondarily) 
generalized epilepsies: a population-based study. Epilepsia 2007;48(6):1128–32. 
[7] Tomson T, Surges R, Delamont R, Haywood S, Hesdorffer DC. Who to target in 
sudden unexpected death in epilepsy prevention and how? Risk factors, 
biomarkers, and intervention study designs. Epilepsia 2016;57(Suppl. 1):4–16. 
[8] Ostendorf A, Ng Y-T. Treatment-resistant Lennox-Gastaut syndrome: therapeutic 
trends, challenges and future directions. Neuropsychiatr Dis Treat 2017;13: 
1131–40. 
[9] Trevathan E, Murphy CC, Yeargin-Allsopp M. Prevalence and descriptive 
epidemiology of Lennox-Gastaut syndrome among Atlanta children. Epilepsia 
1997;38(12):1283–8. 
[10] Rantala H, Putkonen T. Occurrence, outcome, and prognostic factors of infantile 
spasms and Lennox-Gastaut syndrome. Epilepsia 1999;40(3):286–9. 
[11] Reaven NL, Funk SE, Montouris GD, Saurer TB, Story TJ. Burden of illness in 
patients with possible Lennox-Gastaut syndrome: a retrospective claims-based 
study. Epilepsy Behav 2018;88:66–73. 
[12] Myland M, Buysse B, Tsong W, Power GS, Nordli D, Chin RF. Seizure frequency, 
healthcare resource utilisation and mortality in childhood epilepsy: a retrospective 
cohort study using the THIN database. Arch Dis Child 2019;104(11):1070–6. 
[13] Piña-Garza JE, Montouris GD, Vekeman F, Cheng WY, Tuttle E, Giguere-Duval P, 
et al. Assessment of treatment patterns and healthcare costs associated with 
probable Lennox-Gastaut syndrome. Epilepsy Behav 2017;73:46–50. 
[14] Cross JH, Auvin S, Falip M, Striano P, Arzimanoglou A. Expert opinion on the 
management of Lennox–Gastaut syndrome: treatment algorithms and practical 
considerations. Front Neurol 2017;8:505. 
[15] Verrotti A, Striano P, Iapadre G, Zagaroli L, Bonanni P, Coppola G, et al. The 
pharmacological management of Lennox-Gastaut syndrome and critical literature 
review. Seizure 2018;63:17–25. 
[16] Meeraus WH, Petersen I, Chin RF, Knott F, Gilbert R. Childhood epilepsy recorded 
in primary care in the UK. Arch Dis Child 2013;98(3):195–202. 
[17] Proposal for revised classification of epilepsies and epileptic syndromes. 
Commission on Classification and Terminology of the International League Against 
Epilepsy. Epilepsia 1989;30(4):389–99. 
[18] Williams K, Nuwer MR, Buchhalter JR. Diagnostic coding for epilepsy. Continuum 
(Minneap Minn) 2016;22(1):270. 
[19] The Medicines and Healthcare products Regulatory Agency (MHRA). Clinical 
practice research datalink. Available at: https://www.cprd.com/. Accessed 
February 11, 2021. 
[20] Thurman DJ, Beghi E, Begley CE, Berg AT, Buchhalter JR, Ding D, et al. Standards 
for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011;52(Suppl. 7): 
2–26. 
[21] Fonferko-Shadrach B, Lacey AS, White CP, Powell HW, Sawhney IM, Lyons RA, 
et al. Validating epilepsy diagnoses in routinely collected data. Seizure 2017;52: 
195–8. 
[22] Herrett E, Gallagher AM, Bhaskaran K, Forbes H, Mathur R, van Staa T, et al. Data 
resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015; 
44(3):827–36. 
[23] Padmanabhan S, Carty L, Cameron E, Ghosh RE, Williams R, Strongman H. 
Approach to record linkage of primary care data from Clinical Practice Research 
Datalink to other health-related patient data: overview and implications. Eur J 
Epidemiol 2019;34(1):91–9. 
[24] Wolf A, Dedman D, Campbell J, Booth H, Lunn D, Chapman J, et al. Data resource 
profile: Clinical Practice Research Datalink (CPRD) Aurum. Int J Epidemiol 2019; 
48(6). 1740-1740g. 
[25] Hippisley-Cox J. Validity and completeness of the NHS number in primary and 
secondary care: electronic data in England 1991-2013. 2019. Available at: http:// 
eprints.nottingham.ac.uk/3153/. Accessed November 19, 2019. 
[26] Shepherd C, Koepp M, Myland M, Patel K, Miglio C, Siva V, et al. Understanding 
the health economic burden of patients with tuberous sclerosis complex (TSC) with 
epilepsy: a retrospective cohort study in the UK Clinical Practice Research Datalink 
(CPRD). BMJ Open 2017;7(10):e015236. 
[27] electronic Medicines Compendium (eMC). Inovelon: summary of product 
characteristics (SmPC). Available at: https://www.medicines.org.uk/emc/ 
product/410/smpc. Accessed April 6, 2020. 
[28] von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. 
The Strengthening the Reporting of Observational Studies in Epidemiology 
(STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 
370(9596):1453–7. 
[29] Powell G, Logan J, Kiri V, Borghs S. Trends in antiepileptic drug treatment and 
effectiveness in clinical practice in England from 2003 to 2016: a retrospective 
cohort study using electronic medical records. BMJ Open 2019;9(12):e032551. 
[30] National Institute for Health and Care Excellence (NICE). Epilepsies: diagnosis and 
management. Available at: https://www.nice.org.uk/guidance/cg137/resources/ 
epilepsies-diagnosis-and-management-pdf-35109515407813. Accessed September 
3, 2020. 
[31] Kim HJ, Kim HD, Lee JS, Heo K, Kim D-S, Kang H-C. Long-term prognosis of 
patients with Lennox–Gastaut syndrome in recent decades. Epilepsy Res 2015;110: 
10–9. 
[32] Goldsmith IL, Zupanc ML, Buchhalter JR. Long-term seizure outcome in 74 patients 
with Lennox-Gastaut syndrome: effects of incorporating MRI head imaging in 
defining the cryptogenic subgroup. Epilepsia 2000;41(4):395–9. 
[33] Brodie MJ, Barry SJ, Bamagous GA, Norrie JD, Kwan P. Patterns of treatment 
response in newly diagnosed epilepsy. Neurology 2012;78(20):1548–54. 
[34] Vignoli A, Oggioni G, De Maria G, Peron A, Savini MN, Zambrelli E, et al. Lennox- 
Gastaut syndrome in adulthood: long-term clinical follow-up of 38 patients and 
analysis of their recorded seizures. Epilepsy Behav 2017;77:73–8. 
[35] Autry AR, Trevathan E, Van Naarden Braun K, Yeargin-Allsopp M. Increased risk of 
death among children with Lennox-Gastaut syndrome and infantile spasms. J Child 
Neurol 2010;25(4):441–7. 
[36] Office for National Statistics (ONS). Death registrations, populations and age 
standardised rates, England. Available at: https://www.ons.gov.uk/ 
peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/adhocs/ 
11168deathregistrationspopulationsandagestandardisedratesengland1981to2018. 
Accessed September 2, 2020. 
R.F.M. Chin et al.                                                                                                                                                                                                                               
